SCHEMBL8420393

SCHEMBL8420393

Cc1noc(C)c1-c1nc(CN2CCC(C(=O)N3CCN(Cc4ccccc4Br)CC3)CC2)no1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ LMNA P02545 4/20 0.44
▸ TP53 P04637 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ GAA P10253 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ KDM4E B2RXH2 3/20 0.42
▸ USP2 O75604 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ RORC P51449 2/20 0.41
▸ DHODH Q02127 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ PHGDH O43175 1/20 0.41
▸ FAAH O00519 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14456686 0.78 TSHR (0.48) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL14456706 0.76 TSHR (0.48) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL8420394 0.74 KMT2A (0.55) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL14456691 0.74 TSHR (0.48) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL14456744 0.73 KMT2A (0.56) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL14456705 0.73 KDM4E (0.53) ALDH1A1LMNAMEN1KMT2AHPGD
SCHEMBL8223179 0.73 TSHR (0.49) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL14456685 0.71 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL8230258 0.71 TSHR (0.49) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL14456681 0.70 KMT2A (0.52) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238688-B2 Piperidine compounds SCHERING CORPORATION (US) 2007-07-03 — — US disclosed
US-7238688-B2 Piperidine compounds SCHERING CORPORATION (US) 2007-07-03 — — US disclosed
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant SCHERING CORPORATION 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142369-A1 Combination of an H3 antagonist/inverse agonist and an appetite suppressant CNR2, GPR119, GLP1R ALDH1A1 3184/4885SMN1; SMN2 4298/4885LMNA 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback